Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
EGFR monoclonal antibody plus platinum-based chemotherapy
9 evidence topics · 6 sources
FDA-approved first-line indication: cetuximab with platinum-based therapy and fluorouracil
EXTREME design and regimen
EXTREME efficacy in the label
| Endpoint | Cetuximab with platinum-based therapy and fluorouracil | Platinum-based therapy and fluorouracil |
|---|---|---|
| Participants | “(n=222)” | “(n=220)” |
| Median OS, months | “10.1” | “7.4” |
| OS hazard ratio (95% CI) | “0.80 (0.64, 0.98)” | Reference |
| Median PFS, months | “5.5” | “3.3” |
| PFS hazard ratio (95% CI) | “0.57 (0.46, 0.72)” | Reference |
| ORR | “35.6%” | “19.5%” |
EXTREME primary publication
“Adding cetuximab to platinum-based chemotherapy with fluorouracil (platinum-fluorouracil) significantly prolonged the median overall survival from 7.4 months in the chemotherapy-alone group to 10.1 months in the group that received chemotherapy plus cetuximab (hazard ratio for death, 0.80; 95% confidence interval, 0.64 to 0.99; P=0.04).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The addition of cetuximab prolonged the median progression-free survival time from 3.3 to 5.6 months (hazard ratio for progression, 0.54; P<0.001) and increased the response rate from 20% to 36% (P<0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Sepsis occurred in 9 patients in the cetuximab group and in 1 patient in the chemotherapy-alone group (P=0.02).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of 219 patients receiving cetuximab, 9% had grade 3 skin reactions and 3% had grade 3 or 4 infusion-related reactions.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
EXTREME safety in the label
Docetaxel, cisplatin, and cetuximab versus EXTREME: TPExtreme
“The TPEx regimen consisted of docetaxel 75 mg/m2 and cisplatin 75 mg/m2, both intravenously on day 1, and cetuximab on days 1, 8, and 15 (intravenously 400 mg/m2 on day 1 of cycle 1 and 250 mg/m2 weekly subsequently).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Overall survival did not differ significantly between the groups (median 14·5 months [95% CI 12·5-15·7] in the TPEx group and 13·4 months [12·2-15·4] in the EXTREME group; hazard ratio 0·89 [95% CI 0·74-1·08]; p=0·23).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“214 (81%) of 263 patients in the TPEx group versus 246 (93%) of 265 patients in the EXTREME group had grade 3 or worse adverse events during chemotherapy (p<0·0001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The TPEx regimen could provide an alternative to standard of care with the EXTREME regimen in the first-line treatment of patients with recurrent or metastatic HNSCC, especially for those who might not be good candidates for up-front pembrolizumab treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cetuximab with chemotherapy as the KEYNOTE-048 comparator
“239 (83%) of 287 in the cetuximab with chemotherapy group” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Adverse events led to death in 25 (8%) participants in the pembrolizumab alone group, 32 (12%) in the pembrolizumab with chemotherapy group, and 28 (10%) in the cetuximab with chemotherapy group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote